383 related articles for article (PubMed ID: 25331768)
1. Pembrolizumab: first global approval.
Poole RM
Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab: A Review in Advanced Melanoma.
Deeks ED
Drugs; 2016 Mar; 76(3):375-86. PubMed ID: 26846323
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
4. Toripalimab: First Global Approval.
Keam SJ
Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
[TBL] [Abstract][Full Text] [Related]
5. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
11. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
14. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab use for the treatment of advanced melanoma.
Specenier P
Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
Barone A; Hazarika M; Theoret MR; Mishra-Kalyani P; Chen H; He K; Sridhara R; Subramaniam S; Pfuma E; Wang Y; Li H; Zhao H; Zirkelbach JF; Keegan P; Pazdur R
Clin Cancer Res; 2017 Oct; 23(19):5661-5665. PubMed ID: 28179454
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab (Keytruda) for metastatic melanoma.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538981
[No Abstract] [Full Text] [Related]
20. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
Gangadhar TC; Hwu WJ; Postow MA; Hamid O; Daud A; Dronca R; Joseph R; O'Day SJ; Hodi FS; Pavlick AC; Kluger H; Oxborough RP; Yang A; Gazdoiu M; Kush DA; Ebbinghaus S; Salama AKS
J Immunother; 2017; 40(9):334-340. PubMed ID: 29028788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
